Merck acquires Mochida diabetes projects but few details for now
This article was originally published in Scrip
Executive Summary
Merck & Co has licensed from Mochida a portfolio of drug candidates for type 2 diabetes, acquiring exclusive worldwide rights to develop, manufacture and commercialise the molecules in return for undisclosed up front, milestone and royalty payments.